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Abstract
Background: The aim of this prospective placebo-controlled pilot study was to evaluate short-term effects of a
mouthrinse containing aluminium triformate (ATF) on gingival inflammation and plaque formation in periodontal
patients who are in the maintenance phase. ATF has styptic (astringent) and anti-inflammatory effects.
Methods: Forty non-smoking periodontal patients with modified sulcus bleeding index (MSBI) ≥40 % were randomly
divided into two groups. The participants received a masked mouthrinse (ATF or placebo) and were instructed with the
rinsing protocol of 3 daily rinses during 30 s for 7 days. One blinded investigator (CE) performed all clinical examinations.
The primary outcome was reduction in gingival inflammation as measured by MSBI. The secondary outcomes were
reduction of the amount of plaque as measured by plaque index (PI) and approximal plaque index (API) and the
occurrence of side effects. The patients were evaluated at the start and the end of the rinsing period, including the
compliance of the patients.
Results: MSBI was reduced in both groups compared to baseline, but the ATF group showed significantly more
reduction in MSBI compared to the placebo group (ATF: 17.6 %, placebo: 7.6 %, p = 0.035). ATF and placebo had no
effects on dental plaque. Patients reported ATF mouthrinse not to have side effects other than oral sensation, whereas
compliance of the patients was good. Almost all patients in the ATF group reported reduction of gum bleeding after
1 week of rinsing with ATF.
Conclusions: This short-term pilot clinical trial is a firm basis to design a long-term controlled clinical trial to show
whether ATF helps to inhibit further periodontal breakdown in maintenance patients with high MSBI.
Trial registration: This trial was registered in the WHO International Clinical Trials Registry Platform as DRKS00007672,
date of registration: 21/01/2015.
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Background
The link between oral health and general health is be-
coming generally accepted. Prevention of oral inflamma-
tory diseases is considered to be a key element of good
oral and systemic health [1]. Tools and chemical com-
pounds in addition to mechanical plaque control may be
helpful to support oral health. Additional chemical
plaque control as part of domestic oral hygiene has al-
ways been playing an important role in the treatment of
gingival inflammation [2, 3].
Patients with periodontitis need to be enrolled in a
periodontal treatment protocol. During the initial visit,
the patient’s medical and dental history is evaluated and
clinical examinations and radiographic analyses are per-
formed. The patients are being informed that periodon-
titis is an irreversible disease and that progress can be
arrested by proper treatment. Periodontal treatment in-
cludes non-surgical and surgical procedures and domes-
tic oral hygiene regimes. The maintenance phase after
periodontal treatment is as important as the treatment
itself and plays a decisive role whether the long-term
outcome is successful or not [4]. Continuous domestic
oral hygiene is indispensable to reach this aim and suit-
able antiseptics may help.
Chlorhexidine digluconate (CHX) is currently considered
to be the most effective antiseptic mouthrinse due to its
high substantivity and strong anti-bacterial effects and has
been used in dentistry for many decades as liquid or gel [5].
Numerous studies have confirmed its efficacy in inhibition
of plaque formation and reduction of gingival inflammation
[6, 7]. CHX-containing mouthrinses have a significant anti-
bacterial effect up to 7 h after its application [8]. Its efficacy
is similar in mouthrinses with and without alcohol [9].
However, CHX has side effects such as reversible dysgeusia,
black hairy tongue and tooth discolorations [5, 10–12] and
is therefore not suitable for daily use in long-term peri-
odontal maintenance. As a consequence, the search for ef-
fective alternatives without side effects continues.
Novel rinsing solutions should be tested for their applica-
tion in periodontal maintenance for efficacy and side ef-
fects. Aluminium triformate (ATF), an aluminium salt, has
been used for several decades in Europe to control “bleed-
ing gums” and is considered to be safe for daily use. Other
compounds of aluminium salts (aluminium-containing
mouthrinses) have shown a reducing effect on bacterial
growth and plaque formation [13, 14]. Application of alum
(in combination with salt and vinegar) for mouth rinsing
was advocated by Hippocrates approx. 2400 years ago [15].
Aluminium and other similar metals (polyvalent cations)
are widely used in dental products [14]. ATF is available
since 1967, but besides some clinical trials in the 80ies of
last century that did not meet todays’ standards of good
clinical practice, studies have not been performed so far to
test its efficacy in the periodontal maintenance phase. ATF
is likely anti-inflammatory due to its astringent characteris-
tics, but data are not available for its effects on gingival in-
flammation and plaque formation. ATF creates a protective
surface of denaturated keratins and other proteins as a col-
loidal layer through ionic bonds with proteins of the gin-
giva preventing penetration of bacterial compounds such
as endotoxins into the underlying connective tissue.
The aim of this clinical short-term pilot study was to
analyze the effects of ATF as active component in a
commercially-available mouthrinse (Cional®; Kreussler &
Co. GmbH, Wiesbaden, Germany) as an adjunct to mech-
anical oral hygiene in the maintenance phase of periodontal
patients. The primary hypothesis was that the use of ATF
leads to a stronger reduction of gingival inflammation than
placebo. The secondary hypothesis was that the use of ATF
reduces plaque formation and does not have significant side
effects whereas the compliance of patients is good.
Methods
Experimental design
A pilot randomized placebo-controlled, 1-week double
blind clinical trial with parallel groups was designed.
The mouthrinse containing ATF is freely available with-
out prescription at the pharmacy to be used for a period
of maximally one week. We considered it necessary first
to perform a short-term study as a pilot for an extensive
clinical trial for two reasons: 1° we wanted to test the
compliance of the patients who participated in the study
and 2° we wanted to monitor side effects. Side effects
such as allergic reaction or skin irritation have been re-
ported as possible side effects. However, ATF-containing
mouthrinse has been used for over 30 years and side ef-
fects have not been reported thus far.
Study participants
Consecutive periodontal patients were screened at the
Department of Operative Dentistry at the University
Medical Center (Mainz, Germany) during August and
September 2013. Patients who met the inclusion and ex-
clusion criteria were recruited for enrollment.
The following patient inclusion criteria were applied:
– History of chronic periodontitis, having had active
periodontal treatment including non-surgical and
surgical therapies, and being in maintenance for
≥1 year;
– ≥18 years old;
– Willing to participate and willing to sign the
informed consent;
– Having a modified sulcus bleeding index (MSBI)
of ≥40 % [16];
– No pocket depths ≥6 mm;
– At least 20 teeth (at least 5 teeth in each quadrant);
– Systemically healthy.
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Exclusion criteria:
– Known hypersensitivity to ATF;
– Known hypersensitivity to other ingredients of
Cional® (Cremophor RH40, peppermint oil, mint oil,
propylene glycol, glycerol);
– Any anti-inflammatory or antibiotic therapy < 3 months
before treatment;
– Any other treatment during the study;
– Smoker;
– Pregnancy or wish for pregnancy;
– Lactating women;
– Participation in another clinical study;




After a careful medical health evaluation, the oral health
examination was carried out at the screening visit. The
investigator (CE) controlled the inclusion/exclusion cri-
teria and informed the patients about the details and
aim of the study. The subjects signed the informed con-
sent form when they accepted to participate voluntarily
in the clinical trial.
Baseline visit
At the baseline visit, each participant was orally in-
vestigated (see below) and received an individual trial
number. Following the recruitment, the patients were
randomly allocated to either test or control group.
Randomization was performed using random numbers
from a computer-generated list provided by the
manufacturer. Both, dentists and participants were
masked to group allocation. All patients received their
assigned product kit containing a non-labeled bottle
(coded with numbers) of a concentrate that contained
either a solution of ATF or the same solution but
without ATF (placebo) and a special scaled container
to dilute the rinsing solution with water. The patients
were trained to mix the solution and each subject
was given a written instruction (rinsing protocol) on
how to use and dilute the mouthrinse. The rinsing
solution consisted of 2.5 ml ATF or placebo from the
masked bottle, which was to be diluted with water to
50 ml (Fig. 1). The participants were instructed to
rinse 3 times daily for 30 s.
To check the compliance, the subjects had to make a
note of the date, the time, the solution volume in millili-
ters and the rinsing time in seconds. The rinsing proto-
col served both to control the duration of the rinse and
the motivation of the patient in terms of a memory aid.
Furthermore, the subjects were asked to complete a
questionnaire concerning the taste of the product, spe-
cial sensation on tongue or mucosa and possible loss of
taste sensation.
One-week reevaluation
After one week of rinsing, the used bottles as well as
compliance forms were collected and the patients were
orally investigated (see below) and asked for occurrence
of any adverse effects.
Clinical parameters
One calibrated examiner (CE), who was blinded for the
content of the mouthrinse, performed all oral investiga-
tions. The gingival condition was evaluated during the
baseline visit using MSBI (Additional file 1) and plaque
was measured using the plaque index (PI) [17] and
approximal plaque index (API) (Additional file 1) using
plaque disclosing tablets (PD Produits Dentaires SA,
Vevey, Switzerland) for 30 s and subsequent water rinsing.
The clinical examinations were repeated after one week of
rinsing with ATF or placebo mouthrinse (follow-up visit).
Statistical analysis
As the current trial is a pilot study, no formal calcula-
tion on power and group sizes could be made a priori.
Categorical parameters were described using absolute
and relative frequencies, continuous parameters were
Fig. 1 Preparation of the rinsing solution. Each participant received a box containing two bottles of the rinsing concentrate (a and b). Special cups of
2.5 ml (c) and 50 ml (d) were included in the box for the preparation of the rinsing solution. The special cup of 2.5 ml (c) was used to measure the
mouth rinse concentrate that has to be diluted with water in the cup of 50 ml (d)
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described by mean, standard deviation and range. The
age of the patients in the test and control group was
analyzed for differences by the Student t-test. The
gender distribution was analyzed by the Fisher’s exact
test.
The primary endpoint of this study was MSBI. The
baseline and MSBI follow-up levels were compared
between groups using the Mann-Whitney test. The
Wilcoxon signed-rank test within each group (base-
line and follow-up visit) was used to assess the
change in MSBI for ATF and placebo treatment. PI
and API were analyzed in the same way.
Statistical analyses were performed using SPSS 22.0
(Chicago, IL, USA) and SAS 9.4 (Cary, NC, USA,
2002–2012) and the significance level was set at α =
0.05. Sample size calculation was performed using
nQuery Advisor 5.0 (1995–2002, Janet Elashoff ).
Results
Study population and patient characteristics
A total of 101 periodontal patients were assessed for eli-
gibility and 42 met the inclusion and exclusion criteria
and were enrolled (Fig. 2). One patient declined to par-
ticipate and one patient withdrew. Thus, 40 patients
were randomized and equally allocated to either the
ATF group or the placebo group. All participants (n =
40) continued until the end of study and for all patients
complete data sets were available (Fig. 2).
A total of 101 periodontal patients were assessed for
eligibility. The age of participants ranged between 31
and 78 years and the majority of patients was female
(65 % in the ATF group and 90 % in the placebo group).
The mean age (60.6 and 58.6, respectively) did not differ
between the ATF group and placebo group (Table 1).
The number of teeth per group was comparable (25.9
teeth in the ATF group and 24.4 in the placebo group).
The relative frequency of residual pockets was similar as
well in the ATF group and placebo group (18.1 ± 12.3
and 17.1 ± 13.1 %, respectively; Table 1).
Clinical outcomes
The analysis of the data showed a notable improvement
of the MSBI values in both groups after one week of
rinsing (a reduction from 62.8 to 45.2 % for the ATF
group and from 59.2 to 51.6 % for the placebo group at
baseline and after 1 week rinsing, respectively; Table 2).
The reduction in MSBI was significantly higher in the
ATF group (p = 0.035).
Fig. 2 Study flow diagram according to CONSORT 2010
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Oral hygiene and the amount of dental plaque were eval-
uated, analyzing PI and API. The differences of PI and API
at baseline and after 1 week of rinsing were not significant
(p = 0.947 for PI and p = 0.495 for API; Table 2).
Compliance and subjective outcomes
All subjects (n = 40) returned the forms containing de-
tails about date, solution volume and rinsing time. All
patients had rinsed during the entire week. Table 3
shows the subjective outcomes of the participants with
respect to taste, oral sensations and personal assessment
during the rinsing time. None of the participants com-
plained about an unpleasant taste or negative or adverse
effects (Table 3).
On the other hand, patients did report on oral sensation.
The majority of participants that had applied the ATF
mouthrinse reported mouth dryness directly after rinsing,
roughness of the surface of the teeth, tongue and mucosa,
astringent feeling of the mucosa, furry sensation of the
oral cavity after rinsing and metallic taste shortly after
rinsing. Interestingly, 19 out of 20 participants in the ATF
group reported a reduction of gum bleeding during
domestic oral hygiene procedures (Table 3).
Discussion
The present double blind placebo-controlled pilot trial is
the first in vivo study that evaluates the efficacy of an
ATF-containing mouthrinse used by periodontal patients
in the maintenance phase. Fourty patients were enrolled
and have completed this study. The primary hypothesis
of this study was that ATF reduces the MSBI more
than placebo without significant side effects has been
confirmed.
Table 1 Demographic data of the patients included in the study
Group ATF (n = 20) Placebo (n = 20) p-Value
Age 60.6 ± 9.4 58.6 ± 10.1 0.636
Range 46–78 31–75
Gender
Female 13 (65 %) 18 (90 %) 0.058
Male 7 (35 %) 2 (10 %)
Number of teeth 25.8 ± 2.9 24.3 ± 2.5 0.445
Number of sites 155.4 ± 18.5 146.7 ± 15.7 0.149
Range 120–186 129–174
Number of residual pockets (4–5 mm) 28 ± 20.3 26.7 ± 21.1 0.440
Range (1–86) (9–93)
Frequency of residual pockets (%) 18.1 ± 12.3 17.1 ± 13.1 0.398
Values represent descriptive means and standard deviations
Table 2 Clinical parameters at baseline and after one week rinsing (reevaluation)
Clinical parameter ATF (n = 20) Placebo (n = 20) p-value (inter-group differences)
Primary outcome:
MSBI Baseline 62.8 ± 17.1 59.2 ± 14.8 0.529
Reevaluation 45.2 ± 18.9 51.6 ± 19.5 0.383
p-value (intra-group differences) 0.001 0.018
Reduction 17.6 ± 13.8 7.6 ± 11.3 0.035
Secondary outcome:
PI Baseline 0.7 ± 0.5 0.7 ± 0.4 0.640
Reevaluation 0.8 ± 0.5 0.7 ± 0.4 0.445
p-value (intra-group differences) 0.17 0.34
Reduction 0.09 ± 0.27 0.06 ± 0.26 0.947
API Baseline 52.2 ± 19.1 43.3 ± 14.7 0.157
Reevaluation 57.3 ± 20.8 45.1 ± 15.9 0.056
p-value (intra-group differences) 0.177 0.602
Reduction 5.1 ± 14.9 1.8 ± 12.0 0.495
Values represent descriptive means and standard deviations for all indices
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After a period of 7 days, there was a notable reduction
in gingival bleeding in both groups. The comparison be-
tween the two groups showed a significantly higher re-
duction in gingival bleeding as assessed by MSBI in the
ATF group. This is consistent with patients’ subjective
experience in the ATF group of reduced sulcus bleeding
after rinsing. PI and API were not affected during this
short-term application of an ATF-containing mou-
thrinse. It should be noted that the current rinsing
period is relatively short, long-term effects of the rinsing
with ATF need to be investigated. This pilot study was
performed to demonstrate whether MSBI, PI and API
were affected by an ATF-containing mouthrinse without
side effects and whether the compliance of the patients
included in the study was good.
This study was a pilot study and therefore not necessarily
powered to detect significant differences between treat-
ments. In this study, the estimated probability that ATF
leads to a stronger decrease in MSBI (P(ΔMSBIATF
<ΔMSBIPlacebo)) was 0.3125. When calculating sample size
and power under the assumption that P(ΔMSBIATF
<ΔMSBIPlacebo) = 0.3125 and significance level α = 0.05, 38
patients per group are needed to demonstrate this effect
with 80 % power and 50 patients are needed to demonstrate
this effect with 90 % power. With 20 patients per group, the
calculated power is 53 %. Hence, further studies should in-
clude at least 100 patients in order to demonstrate efficacy
of ATF.
The improvement of the MSBI values in the placebo
group can be explained by the Hawthorne effect [18]. This
phenomenon is considered to be based on increased
attention, e.g. due to the participation in a clinical trial
and the consciousness of being evaluated, leading to an
improvement of productivity, or, in this case, a reduction
in MSBI in the placebo group because of an improved oral
hygiene during the study. However, a similar Hawthorne
effect must be present in the ATF group, too. Because
both patients and investigator were masked with respect
to treatment, it is unlikely, that this effect differs between
groups. The reduction in MSBI was significantly stronger
in the ATF group than in the placebo group, which points
at a true effect of ATF on MSBI.
Lang et al. [19] demonstrated the correlation between
the amount of gingival bleeding and tooth survival in
patients during periodontal maintenance. It was shown
that periodontal patients with bleeding ≥16 % on prob-
ing had a higher risk of losing attachment than patients
with <16 % bleeding on probing. After 4 consecutive
maintenance appointments, patients with no bleeding on
probing had a 20-fold lower risk of attachment loss than
patients with bleeding on probing at the 4 maintenance
appointments. These data indicate the importance of
oral hygiene and control of gingival bleeding during the
maintenance phase.
Ramberg et al. [20] showed a correlation between gin-
gival inflammation and de novo plaque formation. Re-
duced gingival inflammation lowers the amount of
crevicular fluid that contains proteins, which are metab-
olized by plaque microorganisms. As the quantity of cre-
vicular fluid correlates with the grade of gingiva
inflammation, a reduction of sulcus irritation decreases
the inflammation and therefore prevents de novo plaque
formation. Furthermore, Van der Velden [21] stated that
gingival fluid is the major cause of de novo plaque for-
mation. However, neither ATF rinse nor placebo rinse
had any effect on the amount of dental plaque during
the short experimental period of 7 days in our study.
Putt et al. [14] showed a significant reduction in the
amount of plaque after 2 and 4 weeks of rinsing and
thus, it may well be that longer rinsing periods show
effects on plaque levels as well.
With respect to the patients’ evaluation reports, ATF
mouthrinse seems to be safe and not causing harmful
side effects. Almost all patients in the ATF group re-
ported the rough sensation of gingiva and teeth surface
accompanied with a metallic taste. These sensations can
be clearly explained by the astringent properties of alu-
minium solutions [22]. However, these sensations disap-
peared after a few minutes and not one patient indicated
a desire to stop the rinsing, thus it is concluded that
compliance of the patients included in the study is good.
The fast reduction in gingival bleeding may be useful
as a pre-surgical measure in patients with inflamed gin-
giva. For protocols in which authors propose immediate
periodontal surgery (without initial therapy) in patients
with advanced periodontitis [23], it can be recom-
mended that patients rinse with ATF during one week
before surgery; the styptic effect of ATF may well be
beneficial, but this application in untreated periodontitis








Reduction in taste sensation 0 0
Oral sensation
Mouth dryness directly after rinsing 19 0
Roughness surface of the teeth, tongue and
mucosa
20 0
Astringent feeling of the mucosa 18 0
Furry sensation of the oral cavity after rinsing 19 0
Metallic taste shortly after rinsing 19 0
Reduction of the gum bleeding during domestic
oral hygiene procedures
19 6
Values represent absolute numbers of individuals with positive responses
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patients is not yet tested and needs further investigation.
ATF rinse may also be beneficial for patients with fixed
orthodontic appliances during an acute period of
gingival inflammation that are at risk for temporary
periodontal destructive processes [24].
Conclusions
ATF mouthrinse solution appears to be a promising ad-
junct to mechanical tools in the periodontal mainten-
ance phase in our short-term pilot clinical trial. A long-
term trial with a larger number of participants is needed
to confirm our findings. The current study shows that
the ATF rinse solution is well accepted by patients and
does not have major and long-lasting side effects.
Additional file
Additional file 1: Modified SBI and API (Lange, [16]). (DOCX 73 kb)
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